Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study

被引：0
|
作者：
Bai, Xueli
Chen, Yiwen
Zhang, Junlei
Hu, Wendi
Li, Xiang
Shen, Yan
Zhang, Min
Wu, Jian
Gao, Shunliang
Yu, Jun
Que, Risheng
Zhang, Yun
Yang, Fuchun
Xia, Weiliang
Zhang, Aibin
Tang, Xiaofeng
Liang, Tingbo
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4108
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparing the efficacy and safety of TACE combined with donafenib or lenvatinib in the treatment of unresectable hepatocellular carcinoma.
    Wei, Ning
    Lu, Dong
    Zhou, Chunze
    Cheng, Delei
    Zhang, Zhengfeng
    Zhang, Xingming
    Xiao, Jingkun
    Lv, Weifu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
    Liu, S.
    Lin, S.
    Luo, H.
    Luo, J.
    Mo, W.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S78 - S79
  • [34] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [35] Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
    Wu, Xu-Kun
    Yang, Lan-Fang
    Chen, Yu-Feng
    Chen, Zhong-Wu
    Lu, Hao
    Shen, Xue-Yi
    Chi, Min-Hui
    Wang, Liang
    Zhang, Hui
    Chen, Jia-Fei
    Huang, Jing-Yao
    Zeng, Yong-Yi
    Yan, Mao-Lin
    Zhang, Zhi-Bo
    ECLINICALMEDICINE, 2024, 67
  • [36] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
  • [37] Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
    Qu, Shuping
    Zhang, Xiaobing
    Wu, Yutian
    Meng, Yan
    Pan, Hongyu
    Fang, Qiang
    Hu, Lei
    Zhang, Jin
    Wang, Ruoyu
    Wei, Lixin
    Wu, Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
  • [39] The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs).
    Li, Zhifang
    Chen, Meixia
    Ming, Qianyi
    Zhang, Yan
    Feng, Kaichao
    Mei, Qian
    Liu, Yang
    Han, Weidong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 504 - 504
  • [40] A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB IN PATIENTS WITH RECURRENT OLIGODENDROGLIOMA: TRIALS IN PROGRESS
    Bagley, Stephen
    Nasrallah, MacLean
    O'Rourke, Donald
    Hussain, Jasmin
    Maloney-Wilensky, Eileen
    Prior, Timothy
    Brem, Steven
    Desai, Arati
    NEURO-ONCOLOGY, 2019, 21 : 219 - 219
12345